ACS / Antithrombotics - S. Wassmann

ACS / Antithrombotics - S. Wassmann

[TCTAP 2021 Virtual] TCTAP Workshop - IV. AntithromboticsПодробнее

[TCTAP 2021 Virtual] TCTAP Workshop - IV. Antithrombotics

AF and ACS - How many antithrombotics and for how longПодробнее

AF and ACS - How many antithrombotics and for how long

ACS Chemical Neuroscience : Modulation of Alzheimer’s Aβ Protofilament-Membrane Interactions...Подробнее

ACS Chemical Neuroscience : Modulation of Alzheimer’s Aβ Protofilament-Membrane Interactions...

ACS / Antithrombotics - S. WassmannПодробнее

ACS / Antithrombotics - S. Wassmann

Anticoagulants and antiplatelet drugs - S Wassmann and P WidimskyПодробнее

Anticoagulants and antiplatelet drugs - S Wassmann and P Widimsky

ACS / AntithromboticsПодробнее

ACS / Antithrombotics

Examples from clinical trials - S. WassmannПодробнее

Examples from clinical trials - S. Wassmann

Examples from clinical trials - S. WassmannПодробнее

Examples from clinical trials - S. Wassmann

ACIST CVi - GermanПодробнее

ACIST CVi - German

ACIST AT X65 - GermanПодробнее

ACIST AT X65 - German

ACIST HDi - GermanПодробнее

ACIST HDi - German

[TCTAP 2021 Virtual] Hot Topics - IV. AntithromboticsПодробнее

[TCTAP 2021 Virtual] Hot Topics - IV. Antithrombotics

Treating patients with poor-risk cytogenetics with venetoclax and HMAsПодробнее

Treating patients with poor-risk cytogenetics with venetoclax and HMAs

Introduction & welcome – S. WassmanПодробнее

Introduction & welcome – S. Wassman

DOACs in the Anticoagulant Treatment LandscapeПодробнее

DOACs in the Anticoagulant Treatment Landscape

OMass Series BПодробнее

OMass Series B